AAD: Will Sanofi and Regeneron’s Dupixent be a game-changer or just another antibody on the COPD scrapheap?

Despite chronic obstructive pulmonary disease (COPD) being the world’s third most fatal disorder, treatment advances have been limited over the last decade. That could change soon however as Sanofi and Regeneron are investigating Dupixent’s ability to tame the inflammatory disease.